| |
18F-Fluoromisonidazole [F-MISO]
Noninvasive positron emission tomography (PET) imaging evaluates the tumor and regional disease in a ‘‘snapshot’’ fashion and can provide serial quantitative measurements of hypoxia. PET imaging of tissue hypoxia using 18F]fluoromisonidazole (FMISO), the most widely used nitroimidazole imaging agent, was developed few years ago. Positive accumulation of FMISO is proportional to the extent of hypoxia in the pO2 range of a few mm Hg; high FMISO uptake implies a low tissue O2 concentration. [18F]MISO is only sensitive to the presence of hypoxia in viable cells; [18F]MISO is not retained in necrosis because the electron transport chain that reduces the nitroimidazole to a bioreductive alkylating agent is no longer active.
![18F-Fluoromisonidazole [F-MISO]](images/Fmiso.jpg "18F-Fluoromisonidazole [F-MISO]")
Some Applications of [18F] Fluoromisonidazole [F-MISO]
| S.No |
Applications |
Resource |
| 1 |
Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer |
Joseph G. Rajendran, et al.Clin Cancer Res., 2006, 12, 5435. |
| 2 |
Assessment of hypoxia in esophageal carcinomas using 18F-MISO PET |
Ingo Brink, et al. J Nucl Med., 2008, 49 (Supplement 1), 113P |
| 3 |
Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole |
Lee ST, et al. Sem Nucl Med., 2007, 37, 451. |
| 4 |
Quantifying regional hypoxia in human tumors with positron emission tomography of [18F] fluoromisonidazole: a pretherapy study of 37 patients |
Rasey JS, et al. Int J Radiat Oncol Biol Phys., 1996, 36, 417. |
| 5 |
Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. |
Spence et al. Clin Cancer Res., 2008, 14, 2623. |
| 6 |
pO polarography, contrast enhanced color duplex sonography(CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? |
Bernd Gagel, et al. BMC Cancer., 2007, 7 113. |
|
|
